Vimarsana
Biggest News Aggregation in the World

Page 32 - Iological Marker News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Iological Marker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Iological Marker Today - Breaking & Trending Today

How to Detect Myocarditis From Immune Checkpoint Inhibitors - Vimarsana News

How to Detect Myocarditis From Immune Checkpoint Inhibitors

Myocarditis is the most severe complication that can develop during use of immune checkpoint inhibitors, as patients present late and with at least a 50% chance of death.

Strong Link Between Muscle Strength, Mobility and Brain Health - Vimarsana News

Strong Link Between Muscle Strength, Mobility and Brain Health

Higher handgrip strength and better mobility correlate with larger brain volumes in cognitively impaired adults with biomarker evidence of dementia.

Atezolizumab Plus Bevacizumab: A New Standard for Some NSCLC? - Vimarsana News

Atezolizumab Plus Bevacizumab: A New Standard for Some NSCLC?

Encouraging findings with the combination suggest that it could offer a new standard treatment for patients with highly mutated non–small cell lung cancer.

Product of Gut Microbiome Implicated in Heart Failure Risk - Vimarsana News

Product of Gut Microbiome Implicated in Heart Failure Risk

A small molecule produced by the gut microbiome from dietary protein may contribute to development of heart failure and is worth exploring as a possible therapeutic target, researchers say.

Who Benefits From 5 Years of Extended Endocrine Therapy? - Vimarsana News

Who Benefits From 5 Years of Extended Endocrine Therapy?

MammaPrint genomic testing suggests that only patients with low-risk, not ultra-low-risk or high-risk, breast cancer benefit from 5 years of extended endocrine therapy.